A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
Crossref DOI link: https://doi.org/10.1007/s00280-016-3102-y
Published Online: 2016-07-15
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Renouf, D. J.
Hedley, D.
Krzyzanowska, M. K.
Schmuck, M.
Wang, L.
Moore, M. J.
Funding for this research was provided by:
Novartis
License valid from 2016-07-15